Vitamin E, Copper, Beta-Carotene and Vitamin C: study protocols
6 study groups took Vitamin E together with Copper, Beta-Carotene and Vitamin C. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Vitamin E
5 study groups in 3 studies say how much Vitamin E participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 IU to 500 IU, 100% of 5 study groups.
| Daily dose | Study groups |
|---|---|
| 250 IU to 500 IU | 5 |
Dose per serving from research: Beta-Carotene
6 study groups in 4 studies say how much Beta-Carotene participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 100% of 6 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mg to 25 mg | 6 |
Dose per serving from research: Vitamin C
6 study groups in 4 studies say how much Vitamin C participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 100% of 6 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg to 500 mg | 6 |
Commonly used together
6 of 6 study groups took Vitamin E, Copper, Beta-Carotene and Vitamin C with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Zinc | 6 |
6 study groups
| Study | ||||||
|---|---|---|---|---|---|---|
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 400 IU | 2 mg | 15 mg | 500 mg | 8 years | — |
| No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years | 400 IU | 2 mg | 15 mg | 500 mg | 9 years | — |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men | 400 mg | — | 17.2 mg | 452 mg | 1 day | 15 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration | 400 IU | 2 mg | 15 mg | 500 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 400 IU | 2 mg | 15 mg | 500 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 400 IU | — | 15 mg | 500 mg | 5 years | — |